Clinical trials
Carcinoma clinical trials
Below are recruiting carcinoma clinical trials, each written for real people, not researchers. We’re tracking 3,117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07532902RecruitingPhase 1
BMS-986504 with standard treatment for advanced solid tumors
This trial tests a new drug called BMS-986504 alongside standard treatments for certain advanced cancers (mesothelioma, stomach/esophageal cancer, or bladder cancer). The drug targets a specific genetic change (MTAP deletion) that may make cancer cells more vulnerable to treatment. Joining could help you access a new therapy, but it may not be suitable for everyone.
Basking Ridge, New JerseyAges 18 years+ - NCT07530094RecruitingPhase 2
Radiation and chemotherapy with immunotherapy for advanced esophageal cancer
This trial tests a combination of radiation, chemotherapy (cisplatin and paclitaxel), and an immunotherapy drug called camrelizumab for patients with advanced esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if adding immunotherapy improves outcomes compared to standard treatment alone.
Nanjing, JiangsuAges 18–75 - NCT07529873RecruitingPhase 2
Study of two drugs for advanced head and neck cancer
This trial tests a combination of two medications, ficerafusp alfa and nivolumab, for people with head and neck cancer that has progressed after platinum-based treatment. The goal is to see if this combination can help control the cancer.
VillejuifAges 18–75 - NCT06446154RecruitingPhase 2
Fruquintinib after immunotherapy for advanced liver cancer
This trial tests a new drug called fruquintinib for people with advanced liver cancer who have already tried immunotherapy. It may help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT07518602RecruitingPhase 2
Chidamide, Sintilimab, and Bevacizumab for Advanced Neuroendocrine Cancer
This trial tests a combination of three drugs—chidamide (a protein regulator), sintilimab (an immune-boosting antibody), and bevacizumab (a growth-blocking antibody)—for patients with advanced neuroendocrine cancer that has spread or cannot be removed surgically and has progressed despite an initial treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Guangzhou, GuangdongAges 18–75 - NCT07519486RecruitingPhase 2
Nutrition support during cancer treatment before surgery
This trial tests whether intensive nutritional support helps patients with advanced esophageal cancer (a type of squamous cell carcinoma) respond better to treatment before surgery. The goal is to improve how well the cancer shrinks and prepare the body for a successful operation.
Chengdu, SichuanAges 18–80 - NCT07524452RecruitingPhase 3
Becotatug vedotin plus immunotherapy for head and neck cancer
This trial tests a new combination of two drugs—becotatug vedotin (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—given before surgery to treat advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve surgical outcomes for patients with specific cancer markers.
Zhuhai, GuangdongAges 18–75 - NCT04803994RecruitingPhase 3
Atezolizumab plus bevacizumab versus TACE for liver cancer
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
GrazAges 18 years+ - NCT07513389RecruitingPhase 2
HPV throat cancer trial skipping radiation with blood tests
This study tests whether patients with a specific type of HPV-positive throat cancer can safely skip radiation after surgery by using blood tests to monitor for cancer recurrence. The goal is to reduce side effects while keeping patients cancer-free.
Charleston, South CarolinaAges 18 years+ - NCT07509333Recruiting
Personalized treatment planning for older adults with lung cancer
This study helps doctors create a personalized treatment plan for older adults with lung cancer based on a comprehensive review of their health. It aims to choose the best treatment to improve quality of life and outcomes.
Chengdu, SichuanAges 60–90 - NCT07503808RecruitingPhase 1
IDE034 for advanced solid tumors with B7-H3 or PTK7
This study tests a new drug called IDE034 for people with advanced solid tumors that have certain markers (B7-H3 and PTK7). The drug may help by targeting these markers on cancer cells, and the study checks if it is safe and effective.
Denver, ColoradoAges 18 years+ - NCT07498907RecruitingPhase 3
Disitamab vedotin plus radiation for high-risk bladder cancer in kidney tube
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
BeijingAges 18 years+ - NCT07505186RecruitingPhase 2
Immunotherapy and chemotherapy before surgery for esophageal cancer
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
Hangzhou, ChinaAges 18–75 - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT06422403RecruitingPhase 2
Study on giving immunotherapy less often for advanced cancer
This trial tests whether giving certain immunotherapy drugs less often than usual is safe and still works well for people with advanced stomach, liver, or lung cancer. It might mean fewer hospital visits while still controlling the cancer.
SingaporeAges 21–99 - NCT07492914RecruitingPhase 2
Study of pre-surgery drugs for head and neck cancer
This trial tests two medications given before surgery for head and neck cancer. The goal is to see if shrinking the tumor beforehand improves outcomes. If you have operable head and neck squamous cell cancer and are generally healthy, you may be eligible.
Chengdu, SichuanAges 18 years+ - NCT07493668RecruitingPhase 2
Fostrox plus Lenvatinib for advanced liver cancer after immunotherapy
This trial tests whether adding the drug Fostrox to the standard drug Lenvatinib works better than Lenvatinib alone for people with advanced liver cancer that has worsened after initial immunotherapy treatment. It is for those who cannot have surgery and have not had more than one prior cancer treatment.
Seongnam-si, Gyeonggi-doAges 19 years+ - NCT07490262RecruitingPhase 2/Phase 3
Immunotherapy combo for advanced liver cancer as first treatment
This trial tests a new combination of two immunotherapy drugs (IBI310 and sintilimab) as a first treatment for advanced liver cancer that cannot be removed by surgery. It aims to see if this combination is safe and works better than current options.
Hefei, AnhuiAges 18–75 - NCT07480954RecruitingPhase 1/Phase 2
CAR-NK cell therapy for recurrent ovarian cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
Shenzhen, GuangdongAges 18–75 - NCT07489066RecruitingPhase 2
Study of PF-08634404 for early-stage or locally advanced lung cancer
This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.
Huntsville, AlabamaAges 18 years+ - NCT07487896RecruitingPhase 3
YL201 vs. chemo for advanced esophageal cancer after first treatment
This trial tests a new drug called YL201 against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has gotten worse after one prior treatment. The goal is to see if YL201 works better at controlling the cancer.
Anqing, AnhuiAges 18 years+ - NCT07489495RecruitingPhase 3
Belzutifan and zanzalintinib for advanced kidney cancer
This study tests two new drugs, belzutifan and zanzalintinib, for people with advanced kidney cancer that has not responded well to other treatments. The goal is to see if the combination slows down cancer growth.
Marietta, GeorgiaAges 18 years+ - NCT07483307RecruitingPhase 2
Hormone therapy before surgery for lobular breast cancer
This trial tests whether taking hormone therapy before surgery can improve outcomes for women with a specific type of breast cancer called lobular breast cancer. If you qualify, you would receive endocrine therapy for 6 months before your planned breast-conserving surgery.
Basking Ridge, New JerseyAges 50 years+ - NCT07483359RecruitingPhase 2
Combination therapy for advanced liver cancer with portal vein tumor thrombus
This trial tests a combination of liver-directed chemotherapy, targeted therapy, and immunotherapy to shrink advanced liver cancer that has a blood clot in the portal vein (the main vein to the liver). The goal is to make the tumor removable by surgery.
Shenyang, LiaoningAges 18–80
Hear when a new Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carcinoma?
- Yes. Clin2 currently lists 3,117 recruiting carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.